FDA Approves Genentech’s TNKase® in Acute Ischemic Stroke in Adults
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug ...
GlobalData on MSN5d
Genentech wins FDA approval for second stroke treatment
Genentech’s label expansion for TNKase consolidates its market position for pharmacological stroke treatments.
Contract Pharma4d
Genentech’s TNKase Approved by FDA for Treatment of Strokes
The FDA has approved TNKase, a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke (AIS) in ...
Genentech announces FDA approval of TNKase in acute ischemic stroke
Genentech announced that the U.S. Food and Drug Administration has approved TNKase, a thrombolytic or clot-dissolving agent, for the treatment ...
FDA approves TNKase for acute ischemic stroke
The U.S. Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the ...
Morningstar6d
FDA Approves Genentech’s TNKase® in Acute Ischemic Stroke in Adults
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved TNKase® (tenecteplase), a thrombolytic or clot ...
PMLive4d
Roche’s Genentech granted FDA approval for TNKase in acute ischaemic stroke
Roche’s Genentech unit has received approval from the US Food and Drug Administration (FDA) for TNKase (tenecteplase) in ...
EMS11d
FDA approves clot-dissolving agent for treatment of acute ischemic stroke
TNKase — tenecteplase — is the first FDA-approved stroke medicine in nearly 30 years, offering a faster, simpler five-second ...
Fierce Pharma5d
Roche gains label expansion for heart attack medicine TNKase to treat acute ischemic stroke
Genentech has had the lone medicine on the market for the acute treatment of stroke. | Over nearly the last three decades, ...
Endovascular Today5d
Genentech’s TNKase Approved by FDA to Treat Acute Ischemic Stroke in Adults
Genentech, a member of the Roche Group, announced that the FDA has approved the company’s TNKase (tenecteplase) thrombolytic ...
News Medical5d
FDA approves Genentech’s TNKase® in acute ischemic stroke in adults
Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase), a thrombolytic or clot-dissolving agent, for the ...
BioSpace5d
Roche Continues Regulatory Run With Acute Stroke Expansion for Heart Attack Drug
According to Roche subsidiary Genentech, which announced the label expansion on Monday, TNKase is the first new drug for ...